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forced air versus resistive fabric warming
technologies on postoperative infection
rates following orthopaedic implant surgery
in adults
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Abstract
Background: Approximately 70,000 to 75,000 proximal femoral fracture repairs take place in the UK each year.
Hemiarthroplasty is the preferred treatment for adults aged over 60 years. Postoperative infection affects up to
3% of patients and is the single most common reason for early return to theatre. Ultraclean ventilation was introduced
to help mitigate the risk of infection, but it may also contribute to inadvertent perioperative hypothermia, which itself
is a risk for postoperative infection. To counter this, active intraoperative warming is used for all procedures that take
30 min or more. Forced air warming (FAW) and resistive fabric warming (RFW) are the two principal techniques used
for this purpose; they are equally effective in prevention of inadvertent perioperative hypothermia, but it is not known
which is associated with the lowest infection rates. Deep surgical site infection doubles operative costs, triples
investigation costs and quadruples ward costs. The Reducing Implant Infection in Orthopaedics (RIIiO) study
seeks to compare infection rates with FAW versus RFW after hemiarthroplasty for hip fracture. A cost-neutral
intervention capable of reducing postoperative infection rates would likely lead to a change in practice, yield
significant savings for the health economy, reduce overall exposure to antibiotics and improve outcomes following hip
fracture in the elderly. The findings may be transferable to other orthopaedic implant procedures and to non-
orthopaedic surgical specialties.
Methods: RIIiO is a parallel group, open label study randomising hip fracture patients over 60 years of age who
are undergoing hemiarthroplasty to RFW or FAW. Participants are followed up for 3 months. Definitive deep surgical
site infection within 90 days of surgery, the primary endpoint, is determined by a blinded endpoint committee.
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Discussion: Hemiarthroplasty carries a risk of deep surgical site infection of approximately 3%. In order to provide 90%
power to demonstrate an absolute risk reduction of 1%, using a 5% significance level, a full trial would need to recruit
approximately 8630 participants. A pilot study is being conducted in the first instance to demonstrate that recruitment
and data management strategies are appropriate and robust before embarking on a large multi-centre trial.
Trial registration: ISRCTN, ISRCTN74612906. Registered on 27 February 2017.
Keywords: Surgical site infection, intraoperative hypothermia, forced air warming, resistive fabric warming,
hemiarthroplasty
Background
Hip fracture is a common problem globally and a major
cause of hospitalisation in the elderly. Approximately
70,000 to 75,000 proximal femoral fracture repairs take
place in the UK each year, with the number continuing
to rise with the ageing population. Effective treatment
requires early surgery, most commonly with hemiarthro-
plasty. Postoperative infection remains one of the most
serious complications of this procedure, affecting 2.5–
3.5% of patients, and is the single most common reason
for early return to theatre [1]. Additionally, length of
hospitalisation is doubled, further surgery is often re-
quired and the cost of treatment is substantial [2]. Eld-
erly patients who have to undergo re-operation are often
left with impaired mobility and are unable to return to
independent living. Furthermore, mortality after an in-
fective complication is generally three times higher than
that following uncomplicated surgery [3].
There are several factors that influence the risk of
postoperative wound infection, including comorbidities,
preoperative waiting time and the duration of surgery.
Ultraclean ventilation in the operating theatre was intro-
duced to limit the rates of infection. It is most com-
monly delivered through laminar flow canopies, which
are now used in more than 60% of hospitals in the UK
[4]. Nevertheless, a major drawback of laminar air flow
ventilation [5] is that it makes the patient colder than
conventional ventilation, with inadvertent perioperative
hypothermia (IPH) being itself a known risk factor for
infection. Following the demonstration that patient
warming reduces the rate of surgical site infections
(SSIs) in colorectal surgery [6], both the National Insti-
tute for Heath and Care Excellence (NICE) and the
World Health Organization recommended maintenance
of normothermia with active warming devices for all op-
erations lasting longer than 30 min [7, 8].
Numerous intraoperative warming methods exist
[9]. Forced air warming (FAW) – or convective air-
warming transfer – has traditionally been considered the
most effective non-invasive method of transferring heat
to the patient, with systematic reviews conducted a dec-
ade apart showing that FAW is still the dominant tech-
nique in use [10, 11]. Resistive fabric warming (RFW),
an air-free method of warming patients that works on a
similar principle to an electric blanket, thus using con-
duction rather than convection, was included as an op-
tion for perioperative warming in recent NICE
guidelines [12]. A systematic review of 67 randomised
controlled studies from 1964 to October 2015 was not
able to recommend one technique over the other for the
prevention of IPH [11], yet their influence on postopera-
tive infection rate is unknown.
Mobilisation of non-sterile air at floor level by FAW
could potentially be compromising the sterility of the
surgical site [13, 14]. Additionally, despite FAW filtration
systems meeting HEPA standards, potentially pathogenic
organisms have been found in hoses and blower systems
[15–19]. Avidan et al. [16] found that higher airborne
bacterial loads were associated with higher infection
rates in patients kept warm with FAW, but this was not
confirmed in later studies [13, 20, 21] and has been ac-
tively challenged by others [22–24]. Therefore, negating
the protective effects of laminar airflow is highly dis-
puted since the evidence does not directly link disrup-
tion of laminar airflow ventilation by FAW with risk of
infection [25–29]. Until more is known about the poten-
tial influence of FAW on the incidence of SSIs, recent
recommendations to not install laminar airflow in oper-
ating rooms for the purpose of preventing SSIs should
not be implemented [30, 31].
Deep SSIs double operative costs, triple investigation
costs and quadruple ward costs [2]. A cost-neutral inter-
vention capable of reducing postoperative infection rates
would likely lead to a change in practice, yield significant
savings for the health economy and reduce overall
exposure to antibiotics, as well as improve outcomes for
hip fractures in the elderly. The RIIiO study compares
infection rates with FAW or RFW after hemiarthroplasty
for hip fracture. The findings may be transferable to
other non-orthopaedic surgical specialties.
Methods/Design
Study hypothesis and objectives
We postulate that the risk of postoperative ortho-
paedic implant infection may be influenced by the
choice of intraoperative warming technology used to
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prevent IPH during hemiarthroplasty for hip fracture
in elderly patients. RIIiO is a multicentre, parallel
group, open label study randomising adults aged
60 years or over undergoing hemiarthroplasty follow-
ing hip fracture to RFW or FAW. The primary end-
point is the observed event rate for definitive deep SSI
within 90 days as determined by a blinded endpoint
committee. A pilot study is being conducted in the
first instance to inform the recruitment and data man-
agement strategies for the full trial. The pathway for
participants is shown in Fig. 1 and summarised in the
SPIRIT figure in Fig. 2 and SPIRIT checklist in
Additional file 1.
Trial participants and informed consent
Potential participants are identified from admission re-
cords, theatre lists and from daily trauma meetings at
six NHS hospitals in the UK. Determination of eligibil-
ity is based on a review of the case notes and a clinical
assessment in relation to the inclusion and exclusion
criteria. Patients with hip fracture are a surgical priority
and will normally undergo surgery on the next available
operating list. Such patients have a high incidence of
comorbidities, will inevitably have suffered trauma and
are likely to either be in pain or to have received opiate
analgesia. In this emergency setting, it is inappropriate
and not always possible to ask potential participants to
review trial documentation. Given the number of fac-
tors influencing capacity or the ability to communicate
an informed opinion, those patients who are listed for
surgery on the next available operating list are not
approached for consent prior to their surgery. Pre-
operative consent for randomisation is sought from an
appropriate consultee in accordance with section 32, sub-
section 9b of the 2005 Mental Capacity Act in the UK. At
the earliest opportunity after recovery from surgery, ran-
domised participants are provided with the study informa-
tion (Additional file 2) and written personal consent to
continue in the pilot study is sought. For any participant
who continues to lack capacity, postoperative written
agreement from a personal consultee is sought. In all
cases, consent is received by appropriately qualified and
Fig. 1 Flowchart of the participant pathway in the RIIiO pilot study
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Good Clinical Practice-trained research staff. Participants
and their consultees are given the option to withdraw
from the study at any time.
Inclusion and exclusion criteria
Participants must meet all of the following criteria:
(1) Provision of informed consent OR consultee dec-
laration, (2) aged 60 years or over, (3) presenting with
fracture of the hip and (4) scheduled to undergo
hemiarthroplasty.
Patients may not enter the study if any of the
following apply:
(1) Previous surgery or infection of the affected hip, (2)
hip fractures related to polytrauma, (3) patients managed
without hemiarthroplasty or (4) receiving an investigational
medicinal product related to infection. Polytrauma is de-
fined as ‘multiple severe injuries involving three or more
parts of the body’.
Randomisation
Prior to surgery, and after confirmation of a patient’s
eligibility, participants are allocated using simple ran-
domisation, 1:1, in randomly permuted blocks of varying
size without stratification by centre. Randomisation is
through an established software package (MACRO) to
either FAW or direct contact RFW. In the case of
software failure, randomisation envelopes prepared in
advance under the supervision of a qualified statistician
are available to the local study team for immediate use
in the emergency setting. The local research teams are
responsible for randomisation and for informing the
patient’s general practitioner that they are participating
in the study.
Study intervention
Only patients that undergo hemiarthroplasty can be
recruited to this study. During their surgery, the partici-
pant is kept warm as part of their standard care using
the technology to which they have been assigned. Both
FAW and RFW are licenced and established techniques
and are equally effective at preventing IPH [32–34]. Both
warming devices are used in accordance with national
guidelines as defined in NICE CG65. Temperature is
measured just before the induction of anaesthesia, every
30 min during surgery, at the end of surgery and upon
arrival in the recovery room. All thermometers are cali-
brated according to the standard protocol at each site.
Whenever possible, temperature is measured with the
automated ‘SpotOn zfd’ temperature monitoring system.
IPH is defined as a temperature of less than 36 °C at the
end of surgery or upon arrival in the recovery room.
Where necessary for optimal clinical care, additional
warming methods, such as actively warming intravenous
fluids and blood products, may be employed at the dis-
cretion of the supervising clinician.
Fig. 2 SPIRIT figure for the RIIiO pilot study
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Baseline assessments
The following data are recorded at baseline, the majority
being captured from routine clinical care records: (1) age,
(2) sex, (3) estimated height and weight, (4) American So-
ciety of Anaesthesiologists physical status classification, (5)
anatomical side affected, (6) date of admission, (7) date of
surgery, (8) randomisation arm, (9) adherence to random-
isation result, (10) duration of surgery, (11) use of ultra-
clean ventilation in theatre, (12) cemented or uncemented
prosthesis, (13) type of antibiotic-containing cement, (14)
antimicrobial prophylaxis, (15) immuno-suppressants,
(16) comorbidities (active malignancy, history of ischaemic
heart disease, peripheral vascular disease, stroke, demen-
tia, kidney disease/renal failure, diabetes mellitus, rheuma-
toid arthritis, systemic autoimmune disease and HIV), and
(17) quality of life measures. Quality of life measures are
obtained through the EQ-5D-5L questionnaire, which has
been recommended for patients with hip fracture [35]. For
those participants who lack capacity, the EQ-5D-5L ques-
tionnaire is completed by proxy through a consultee [36].
Subsequent assessments
Subsequent assessments are undertaken at 30 (± 7) days
and 90 (± 14) days after surgery. In addition to recording
EQ-5D-5L, the patients’ medical records are consulted for
any indication of deep or superficial SSI. Follow-up data in-
clude (1) date of discharge, (2) duration of hospital stay, (3)
date[s] of readmission[s], (4) date of diagnosis of a potential
deep SSI, (5) whether repeat surgery was performed, (6)
radiological evidence of deep infection, (7) symptoms and
signs indicative of a potential deep SSI (i.e. temperature,
localised pain or tenderness, deep purulence from the
wound or periprosthetic drain, spontaneous deep wound de-
hiscence), (8) results of deep tissue samples taken for histo-
logical analysis, (9) confirmed presence of microorganisms
cultured from deep tissue/fluid samples (Staphylococcus
aureus, coagulase-negative Staphylococcus sp., Streptococ-
cus sp., Enterococcus sp., Pseudomonas sp. and/or other
Gram negative organism[s]), (10) superficial SSI (i.e. involv-
ing only skin and subcutaneous tissues, purulent drainage
from superficial incision, wound deliberately opened by the
medical team due to pain or tenderness, erythema, localised
swelling and/or warmth, positive aseptically obtained speci-
men from superficial incision or subcutaneous tissues (S.
aureus, coagulase-negative Staphylococcus sp., Streptococ-
cus sp., Enterococcus sp., Pseudomonas sp. and/or other
Gram negative organism[s]), or (11) serious adverse events,
including death (i.e. all-cause mortality).
Definitions of deep and superficial SSI
Deep and superficial SSI definitions are adapted from
the Centres for Disease Control SSI criteria published
in January 2016 [37]. Deep SSI is defined by the
following criteria:
1) Infection arising within 90 days of the index
surgery (where day 1 is the procedure date)
AND
2) Involves deep tissues related to the incision (e.g.
fascial and muscle layers, joint space or
periprosthetic region) AND
3) At least one of the following:
i. Purulent drainage from the deep incision or
periprosthetic drain
ii. A deep incision that spontaneously dehisces, or
is deliberately opened or aspirated or biopsied
by a surgeon, physician or other designee and
an organism is identified by a culture- or non-
culture-based microbiologic testing method
performed for purposes of clinical diagnosis or
treatment (e.g. not Active Surveillance Culture/
Testing), or without a culture- or non-culture-
based microbiologic testing method being
performed
iii. An abscess or other evidence of infection
involving the deep incision or periprosthetic
region that is detected on gross anatomical,
histopathological exam or imaging test
Superficial SSI is defined by the following criteria:
a. Infection arising within 30 days of the index surgery
(where day 1 is the procedure date) AND
b. Involves only skin or subcutaneous tissue related to
the incision AND
c. At least one of the following:
i. Purulent drainage from the superficial incision
ii. Organisms identified from an aseptically obtained
specimen from the superficial incision or
subcutaneous tissue by a culture- or non-culture-
based microbiologic testing method which is
performed for purposes of clinical diagnosis or
treatment (e.g. not Active Surveillance Culture/
Testing (ASC/AST)
iii. Superficial incision that is deliberately opened
by a surgeon, physician or other designee and
culture- or non-culture-based testing is not
performed AND
iv. The patient has at least one of the following signs
or symptoms: pain or tenderness, localised
swelling, erythema, heat
v. Diagnosis of a superficial incisional SSI by a
surgeon or physician
Endpoints and limitation of bias
The primary endpoint of the pilot study is the observed
event rate for definitive deep SSI within 90 days of sur-
gery. Secondary endpoints of the study are (1) superficial
SSI, (2) IPH, (3) length of hospital stay, (4) EQ-5D-5L
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measures, (5) resource utilisation and (6) serious adverse
events, including death. Any post-randomisation readmis-
sion, clinic attendance or return to theatre with signs and
symptoms at the site of surgery is considered a potential
primary endpoint. Double blinding is not possible in this
study. Any consequent risk of bias is limited by the use of
a blinded endpoint committee (EPC) comprising clinicians
with expertise in the diagnosis and management of bone
and joint infection. For all potential deep SSIs, the EPC is
provided with a summary of the participant’s medical
records relevant to the clinical episode redacted for per-
sonal identifiers and any information relating to their ran-
domisation or intraoperative thermoregulation. The EPC
confirms if a primary endpoint has been reached. Superfi-
cial SSIs are identified by the local care team.
The number of participants
Hemiarthroplasty carries a risk of deep SSI of approxi-
mately 2.5–3.5%. In order to provide 90% power to dem-
onstrate an absolute risk reduction of 1%, using a 5%
significance level, the full trial will need to recruit
approximately 8630 participants over a 3-year period from
a total of 30 sites (sample size calculations were performed
in Stata, version 14SE [StataCorp, College Station, Texas]).
The primary objective of the pilot study is to demonstrate
that strategies for recruitment and data management for a
trial of this size are appropriate and robust. Thus, there is
no defined upper limit for the number of participants that
can be recruited to the pilot study. Participants are re-
cruited over a minimum period of 12 months at each site.
To be able to keep the number of centres involved in the
full trial to a maximum of 30, each pilot centre will be ex-
pected to recruit an average of two participants per week
in the pilot study. The total number of patients recruited
in the pilot study will be used to confirm the actual num-
ber of sites required for the full trial.
Trial management and safety reporting
The pilot study is co-ordinated by the Brighton and Sus-
sex Clinical Trials Unit and a trial management group.
A trial steering committee (TSC), comprising patient
and public representatives, two independent clinicians
and a statistician, makes recommendations to the trial
management group regarding the conduct of the trial,
recruitment and follow-up rates, and assesses the pro-
gression plan to the full trial based on extrapolation of
data acquired in the pilot study. An independent Data
Safety Monitoring Board (DSMB) evaluates patient
safety and frequency of endpoints in an un-blinded ana-
lysis and makes recommendations to the TSC.
Discussion
A systematic review of 67 RCTs involving patient warming
systems from 1964 to October 2015 could not identify
whether FAW or RFW was more efficient at warming the
patient [11]. To accurately study IPH and its conse-
quences for orthopaedic patients, including postoperative
infection rate, a standardised temperature monitoring
protocol in a prospective trial with robust follow-up and
adherence to CONSORT standards is needed [38]. An ob-
servational study in one hospital over a 2.5-year period
suggested that the risk of developing deep infection up to
60 days after surgery was substantially greater for patients
treated with FAW than RFW [14], but there were signifi-
cant confounding factors in this study. The traditional
assumption that FAW is the most effective non-invasive
method of transferring heat to the body is based on warm-
ing comparisons that did not include RFW. Moreover,
reduced infection rates with FAW have only been demon-
strated, to date, with colorectal surgery [6], which is sig-
nificantly different to orthopaedic trauma surgery. The
RIIiO study will make substantial advances in the scien-
tific understanding of whether or not the choice of patient
warming technology influences the incidence of deep SSI.
The pilot study will inform recruitment and data manage-
ment strategies for such a trial.
Trial status
The RIIiO pilot study began recruiting on April 3, 2017,
in Northumbria Healthcare NHS Foundation Trust and
subsequently in Brighton and Sussex University Hospitals
NHS Trust, Oxford University Hospitals NHS Foundation
Trust, Milton Keynes University Hospital NHS Founda-
tion Trust, Heart of England NHS Foundation Trust,
Sheffield Teaching Hospitals NHS Foundation Trust and
East Kent Hospitals University NHS Foundation Trust.
Recruitment will cease in September 2018 and the pilot
study will end in December 2018.
Additional files
Additional file 1: RIIiO pilot study SPIRIT checklist. (DOC 122 kb)
Additional file 2: RIIiO pilot generic PIS consent form. RIIiO pilot study
generic patient information sheet and consent form: the information
provided to patients and their consultees containing the form used to
record their consent for enrolment in the trial. (PDF 529 kb)
Additional file 3: Full ethically approved RIIiO pilot study protocol.
(PDF 1940 kb)
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